Allyx sets Phase II plans in motion after Phase Ia results for Alzheimer’s drug
Allyx Therapeutics is planning a Phase II study to demonstrate proof of concept in Alzheimer’s disease with its lead drug…
Alzheimer's disease
-
-
Annovis looks to advance pivotal Alzheimer’s and Parkinson’s drug studies
Annovis Bio is working to progress its lead oral drug for Alzheimer’s disease (AD) and Parkinson’s disease (PD) studies as two…
-
Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
Pharma Technology Focus is now available on all devices. Read it for free here We look into the safety issues associated…
-
Expert Insights: Another Failure for BACE1 Drugs Raises Questions about Alzheimer’s Disease Treatments
Johnson & Johnson’s Janssen division has decided to halt the Phase II–III EARLY clinical trial (NCT02569398) of its Alzheimer’s disease…
